Vator Securities advises Chordate Medical on 42 MSEK Rights Issue

23 December 2023

Chordate Medical is a medical technology company that has developed, patented and CE-marked Ozilia® Migraine (formerly K.O.S), a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis.

The treatment has clinically proven efficacy according to a recent study, and is marketed in Finland, Germany, the UK, Italy, Israel, and the Gulf region.

Read More

Vator Securities advises InCoax Networks on 53 MSEK Rights Issue

19 December 2023

InCoax Networks re-purposes existing property coaxial networks in fiber and fixed wireless access (FWA) extension deployments for Communication Service Providers (CSP) globally.

The technology is a high performance, future proof, reliable and cost-effective complement, that reduces installation time and improves take-up rate, to boost digital inclusion and Internet access for all. 

Read More

Vator Securities advises Svenska Aerogel on 51 MSEK Rights Issue

18 December 2023

Svenska Aerogel manufactures and commercializes the mesoporous material Quartzene®. Svenska Aerogel’s business concept is to meet the market’s need for new materials that are in line with global sustainability objectives.

Quartzene® is flexible and can be tailored to different applications to add essential properties to an end product. The Company’s vision is to be the most valued business partner providing pioneering material solutions for a sustainable world.

Read More

Vator Securities advises Saniona on 140 MSEK Rights Issue

15 December 2023

Saniona is an epilepsy focused clinical-stage biopharmaceutical company engaged in the discovery and development of medicines modulating ion channels. Saniona’s epilepsy pipeline includes the Phase 2 ready asset SAN711 positioned for treatment of absence seizures, the preclinical development compound SAN2219 for acute repetitive seizures and the drug-discovery program on Kv7 modulators for refractory focal onset seizures.

Outside epilepsy Saniona has three clinical programs, which are positioned for partnering. The most advanced candidate, tesofensine, has progressed towards regulatory approval for obesity in Mexico by Saniona’s partner Medix, whereas Tesomet™ is ready for Phase 2b for rare eating disorders, and SAN903 is ready for Phase 1 for inflammatory bowel disease.

Read More

Vator Securities advises Howwe Technologies on 15 MSEK Private Placement

13 December 2023

Howwe has developed a market-leading SaaS platform that accelerates customers’ execution & financial results. The SaaS application helps CEOs and their underlying organization with digital strategy execution.

The market for digital strategy execution is underdeveloped with an apparent need for an application to drive execution and digital transformation.

Read More

Vator Securities advises ESTRID on 93 MSEK Private Placement

6 December 2023

ESTRID is a fast-growing Scandinavian razor and body care brand disrupting the European shaving market by gaining market share against established incumbents by offering fairly priced, high-quality products which are 100% vegan.

ESTRID reported SEK 438 million revenue in 2022, a stunning 93% growth compared to 2021. Rapid European growth continues in 2023 with stronger profitability and the Nordics, Germany and the UK as key markets.

Read More

Vator Securities advises ZignSec on 9 MSEK Directed Share Issue

28 November 2023

ZignSec is a technology group in the rapidly growing RegTech industry. The company provides a SaaS platform with real-time digital customer knowledge and ID verification solutions with global reach.

The solutions are used by companies who in turn can optimise their processes to “onboard” both business customers and consumers while ensuring compliance with ever-changing local and global regulatory requirements for Know Your Customer (KYC) and Anti Money Laundering (AML).

Read More

Vator Securities advises WntResearch on 56 MSEK Rights Issue

21 November 2023

WntResearch is an oncology biotech company that develops new therapies to counteract the development of cancer metastases. The company’s research is focused on studying the endogenous protein WNT5A, which has been shown in scientific studies to affect the ability of tumor cells to move and spread in the body.

WntResearch’s drug candidate Foxy-5 is a peptide that mimics the function of WNT5A with the aim of reducing the mobility and spread of cancer cells and thereby preventing metastases from occurring.

Read More